Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

p53-Aggr-Cancer

Financiado

Cerrado

The aggregation of p53 in response to changes in the proteostasis network

The concept of the proteostasis network (PN) represent a systems biology approach to protein deposition diseases (e.g. neurodegenerative diseases, amyloidoses, type II diabetes). The PN includes all the cellular components involve... ver más

07/08/2014

VLAAMS INSTITUUT...

235K€

Presupuesto del proyecto: 235K€

Líder del proyecto

VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-08-07 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

VLAAMS INSTITUUT BIOTECHNOL...

0.00€ | Lider

Proyectos interesantes

PID2021-128408OB-I00

Medical Technol...

Applied Physics

218K€ Cerrado

BFU2016-80234-R

Medical Technol...

Applied Physics

351K€ Cerrado

RTI2018-094739-B-I00

Medical Technol...

Applied Physics

157K€ Cerrado

BFU2013-47710-R

Medical Technol...

Applied Physics

351K€ Cerrado

PID2021-122311NB-I00

Medical Technol...

Applied Physics

212K€ Cerrado

BFU2016-80295-R

Medical Technol...

Applied Physics

157K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 235K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The concept of the proteostasis network (PN) represent a systems biology approach to protein deposition diseases (e.g. neurodegenerative diseases, amyloidoses, type II diabetes). The PN includes all the cellular components involved in the synthesis, folding, and degradation of proteins, as well as the regulatory mechanisms required for maintaining a functioning proteome despite cellular stress, mutations, or protein misfolding. When the misfolded protein load exceeds the capacity of the PN to maintain, protein aggregation can occur. Protein misfolding and subsequent aggregation is already thought to be the main cause of neuronal death in neurodegenerative diseases. Our study on the aggregation of p53, however, is the first report of protein aggregation leading directly to increased cell proliferation of the same cell in which the aggregation occurs by a gain of function mechanism. p53 is a potent tumor suppressor, and it is the most frequently mutated gene in human cancer (approximately half of the cases). We observed that mutant p53 not only strongly aggregated in tumor cells, - thereby already eliminating one copy of p53 – but that it also co-aggregated in a dominant negative way with wild type p53 and its paralogs, p63 and p73, sequestering these tumor suppressors that are pivotal to prevent tumorigenesis. The ability of the PN to cope with mutant or damaged biological material varies with the differentiation stage of cells, as well as deteriorates with cellular senescence. According to our hypothesis, the decline of the PN, particularly its decreasing ability to control aggregation-prone mutant p53 proteins, is one of the contributing factors to the steadily increasing incidence of cancer with age. We are proposing to study the aggregation of mutant p53 proteins in undifferentiated, differentiated, and senescent cells to test our hypothesis and gain information on the key factors keeping p53 aggregation, and tumorigenesis, at bay.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores